Literature DB >> 24172315

Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia.

Stefan Blum1, Stephen Reddel, Judy Spies, Pamela McCombe.   

Abstract

To document the clinical features of Guillain-Barré syndrome (GBS) in Australia, we performed a retrospective analysis of all patients admitted to several hospitals along the East Coast of Australia from 2000 to 2012. Using hospital records, we reviewed all patients with a diagnosis of GBS admitted to seven hospitals. From these, we report information of subjects who fulfilled standard diagnostic criteria. We excluded patients where inadequate information was available or who were under the age of 18. We report the features of 335 patients, in 228 of whom neurophysiological data were available. There were 168 cases of acute inflammatory demyelinating polyneuropathy (AIDP), 17 of acute motor axonal neuropathy (AMAN), 4 of acute motor and sensory axonal neuropathy (AMSAN), and 35 of Miller-Fisher syndrome (MFS). The median age at onset was 52.5 years (18-89 years) with a male : female ratio of 1.61 : 1. Upper respiratory tract infections were the most frequently identified trigger (151 subjects, 44.5%). Most patients were severely affected, with 42.7% of subjects bedbound, and an additional 24% requiring ventilatory support. GBS affects adults of all ages and usually follows a severe clinical course. In contrast to other autoimmune diseases, males are more frequently affected. A wide variety of triggering factors leads to a relatively stereotypical clinical syndrome. The most common variant of GBS in Australia is AIDP. This study shows that the clinical features of GBS in Australia are similar to that previously reported and confirms the male predominance, increased incidence with age, and frequent evidence of peripheral nerve demyelination as features of GBS.
© 2013 Peripheral Nerve Society.

Entities:  

Keywords:  Australia; Guillain-Barré syndrome; acute inflammatory demyelinating polyradiculoneuropathy; epidemiology; seasonal variation

Mesh:

Year:  2013        PMID: 24172315     DOI: 10.1111/jns5.12045

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  6 in total

Review 1.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

Review 2.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

3.  Attenuation of experimental autoimmune neuritis with locally administered lovastatin-encapsulating poly(lactic-co-glycolic) acid nanoparticles.

Authors:  Kelly A Langert; Bruktawit Goshu; Evan B Stubbs
Journal:  J Neurochem       Date:  2016-12-20       Impact factor: 5.372

4.  Incidence of Guillain-Barré syndrome (GBS) in China: A national population-based study.

Authors:  Pei Zheng; De-Cai Tian; Yuwen Xiu; Yongjun Wang; Fu-Dong Shi
Journal:  Lancet Reg Health West Pac       Date:  2021-11-02

5.  The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.

Authors:  Kristy Purnamawati; Jamie Ann-Hui Ong; Siddharth Deshpande; Warren Kok-Yong Tan; Nihar Masurkar; Jackson Kwee Low; Chester Lee Drum
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

Review 6.  Diagnosis and management of Guillain-Barré syndrome in ten steps.

Authors:  Sonja E Leonhard; Melissa R Mandarakas; Francisco A A Gondim; Kathleen Bateman; Maria L B Ferreira; David R Cornblath; Pieter A van Doorn; Mario E Dourado; Richard A C Hughes; Badrul Islam; Susumu Kusunoki; Carlos A Pardo; Ricardo Reisin; James J Sejvar; Nortina Shahrizaila; Cristiane Soares; Thirugnanam Umapathi; Yuzhong Wang; Eppie M Yiu; Hugh J Willison; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2019-09-20       Impact factor: 42.937

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.